The Neurocritical Care Society Announces Trial Results & New Guidelines at their 2014 Annual Meeting
SEATTLE, Aug. 25, 2014 /PRNewswire-USNewswire/ -- Seattle, Washington will host the 2014 Neurocritical Care Society (NCS) Annual Meeting, bringing together the top researchers and healthcare providers in the field. The NCS will present two pivotal trials and unveil two new guidelines at its 2015 Annual Meeting being held at the Seattle Westin Hotel, September 10-14, 2014.
Targeted Temperature Management (TTM), previously known as Therapeutic Hypothermia after Cardiac Arrest, refers to strict temperature control following cardiac arrest. The current practice of strict temperature management is based on evidence that suggests induced hypothermia after cardiac arrest results in improvement of neurological outcomes. However, the TTM trial has concluded that in unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, patients controlled to a core temperature 36°C did just as well as those cooled to 33°C. On September 12, 2014, Dr. Niklas Nielsen, the lead investigator for the TTM study along with other experts will be discussing this controversial study and the best ways to provide neurological protection on post-resuscitation brain.
Dr. David Wright, Principal Investigator of the ProTECT III trial will present the primary results of this study on Saturday Sept 13th. The study was an NIH NINDS funded Phase III clinical trial designed to determine the efficacy of progesterone for the treatment of acute traumatic brain injury (TBI). The study examined whether a 96 hour infusion of progesterone, started within 4 hours of moderate to severe traumatic brain injury, was superior to placebo.
Two new practice guidelines will be presented on September 11, 2014. The Summary Statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care will address important processes that should be monitored in the critically ill neurological patient, how they should be monitored and if monitoring is cost effective and impacts outcome. The NCS, in collaboration with the European Society of Intensive Care Medicine, The Society for Critical Care Medicine and the Latin American Brian Injury Consortium developed this statement to establish guidelines for patient monitoring in the Neuro ICU. The NCS will also present a second guideline, Evidence Based Guidelines for the Management of Large Hemispheric Infarction. Large hemispheric infarction is a devastating disease associated with significant mortality and morbidity with a paucity of data in determining an appropriate course of treatment. This guideline developed in collaboration with the German Society for Neuro-Intensive Care and Emergency Medicine will provide recommendations on the benefits and risks of interventions taking into account the values and preferences of patients.
"We are honored to be able to provide the platform for discussing these important trial results", said Romer Geocadin, Vice President and Program Chair of the 2014 NCS Meeting.
Learn about the full 2014 NCS Annual Meeting Program
The Neurocritical Care Society is an international not-for-profit organization composed of multiprofessional healthcare providers that are dedicated to improve the care and outcomes of patients with life-threatening neurological illnesses by promoting quality patient care, professional collaboration, research, training and advocacy. For additional information or to join, visit www.neurocriticalcare.org.
Neurocritical Care Society Executive Office
SOURCE Neurocritical Care Society